Lundbeck today announces that orphan drug designation has been granted to Lu AG13909 by the US Food and Drug Administration (FDA) on 12 May 2025 and the European Medicines Agency (EMA) on 20 June 2025 ...

Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO).

Only last month, the Massachusetts-based company was outlining plans to lay off half of its employees in order to focus its ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting ...

Aiming T-cell engagers at autoimmune diseases continues to be a red-hot deal-making target, as evidenced by Otsuka ...

In a human-mouse xenogeneic GvHD (xGvHD) model, ALTB-268 significantly improved survival, reduced disease severity score and body weight loss, and decreased human CD4+ and CD8+ T cells, while ...